Shell crown을 이용하여 기존 국부의치 지대치를 복제한 금관 제작에 관한 연구

임병철 김천대학교 1985 김천대학교 논문집 Vol.6 No.-

A study of the Crown construction using sheel crown made by duplicating the abutmenttooth of the P.O Lim, Byung Chul Abstract From time to time, it is necessary to reconstruct the crown for the abutment tooth of the partial Denture, it has been difficult and lack of accuracy in it’s construction. I studied and discovered a new method of reconstructing the crown, that is rather easir and more accurate than the method bing used, in the following points. 1.It’s good in function and use of the partial Denture ready made, 2.It is good to protect the periodental tissue, and avoid the uneasy feeling, 3.It is so easy and accurate in the procedure of reconstruction, 4.And patient’s charge would be less, because of not reconstructing the partial Denture.

The CROWN Initiative: journal editors invite researchers to develop core outcomes in women’s health

CROWN Initiative 대한부인종양학회 2014 Journal of Gynecologic Oncology Vol.25 No.3

동반생물학적표지자: 개인맞춤 암치료를 향한 경로 제공

Michael J. Duffy,John Crown 대한진단검사의학회 2015 Laboratory Medicine Online Vol.5 No.1

Background: Companion biomarkers are biomarkers that are used in combination with specific therapies and that prospectively help predict likely response or severe toxicity. In this article we review the role of companion biomarkers in guiding treatment in patients with cancer. Content: In addition to the established companion biomarkers such as estrogen receptors and HER 2 (human epidermal growth factor receptor 2) in breast cancer, several new companion biomarkers have become available in recent years. These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. Summary: The availability of companion biomarkers should improve drug efficacy, decrease toxicity, and lead to a more individualized approach to cancer treatment. 배경: 동반생물학적표지자(Companion biomarker)는 특정 치료제와의 조합으로 이용되어 반응성 또는 심한 독성 가능성을 미리 예측할 수 있도록 도와주는 것이다. 이 논문에서는 암 환자에서 치료의 방향을 제시하는 데 있어서의 동반생물학적표지자의 역할이 검토될 것이다. 내용: 유방암에서의 에스트로젠 수용체나 HER 2 (human epidermal growth factor receptor 2)와 같은 이미 확립된 동반생물학적표지자들 뿐 아니라, 최근 수년간 새로운 몇몇 동반생물학적표지자들이 등장하였다. 이들은 항-상피세포 성장인자 수용체 항체(anti-epidermal growth factor receptor antibodies; cetuximab 또는 panitumumab) 치료효과를 보일 것으로 예상되는 진행성 대장암환자들을 선택하기 위한 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) 돌연변이, 진행성 비소세포성폐암(non–small cell lung cancer, 비소세포성폐암) 환자들 중 타이로신활성효소 억제제(tyrosine kinase inhibitors; gefitinib 또는 erlotinib) 치료 적용대상을 선택하기 위한 epidermal growth factor receptor (EGFR) 돌연변이, 항BRAF 제제(vemurafenib and dabrafenib) 치료 대상이 될 수 있는 진행성 흑색종 환자의 선별을 위한 v-raf murine sarcoma viral oncogene homolog B1 (BRAF) 돌연변이, 그리고 crizotinib에 치료효과가 있을 것으로 보이는 비소세포성폐암 환자들을 찾아내기 위한 anaplastic lymphoma receptor tyrosine kinase (ALK) 전위 등이다. 요약: 동반생물학적표지자의 활용은 약제의 효과 향상, 독성 감소를 가져올 것이며, 암 치료에 대한 보다 개인별 최적화된 접근을 가능하게 할 것이다.

Effect of growth hormone overexpression on gastric evacuation rate in coho salmon

Kim, Jin-Hyoung,Chatchaiphan, Satid,Crown, Michelle T.,White, Samantha L.,Devlin, Robert H. Springer-Verlag 2018 Fish physiology and biochemistry Vol.44 No.1

<P>Growth hormone (GH) transgenic (T) coho salmon consistently show remarkably enhanced growth associated with increased appetite and food consumption compared to non-transgenic wild-type (NT) coho salmon. To improve understanding of the mechanism by which GH overexpression mediates food intake and digestion in T fish, feed intake and gastric evacuation rate (over 7 days) were measured in size-matched T and NT coho salmon. T fish displayed greatly enhanced feed intake levels (similar to 2.5-fold), and more than 3-fold increase in gastric evacuation rates relative to NT coho salmon. Despite the differences in feed intake, no differences were noted in the time taken from first ingestion of food to stomach evacuation between genotypes. These results indicate that enhanced feed intake is coupled with an overall increased processing rate to enhance energy intake by T fish. To further investigate the molecular basis of these responses, we examined the messenger RNA (mRNA) levels of several genes in appetite- and gastric-regulation pathways (Agrp1, Bbs, Cart, Cck, Glp, Ghrelin, Grp, Leptin, Mc4r, Npy, and Pomc) by qPCR analyses in the brain (hypothalamus, preoptic area) and pituitary, and in peripheral tissues associated with digestion (liver, stomach, intestine, and adipose tissue). Significant increases in mRNA levels were found for Agrp1 in the preoptic area (POA) of the brain, and Grp and Pomc in pituitary for T coho salmon relative to NT. Mch and Npy showed significantly lower mRNA levels than NT fish in all brain tissues examined across all time-points after feeding. Mc4r and Cart for T showed significantly lower mRNA levels than NT in the POA and hypothalamus, respectively. In the case of peripheral tissues, T fish had lower mRNA levels of Glp and Leptin than NT fish in the intestine and adipose tissue, respectively. Grp, Cck, Bbs, Glp, and Leptin in stomach, adipose tissue, and/or intestine showed significant differences across the time-points after feeding, but Ghrelin showed no significant difference between T and NT fish in all tested tissues.</P>

금속소부도재관에 있어서 금속하부구조의 설계에 관한 고찰

박명자 김천대학교 1989 김천대학교 논문집 Vol.10 No.-

인류는 기원전 4000년경 부터 도재를 생활용품에 이용하여 왔으며 18세기 프랑스에서 도재가 치과영역에 이용된 이래 많은 연구와 발전을 가져왔다.

Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials

( Jeong Heo ),( Yoon Jun Kim ),( Jin-woo Lee ),( Ji Hoon Kim ),( Young-suk Lim ),( Kwang-hyub Han ),( Sook-hyang Jeong ),( Mong Cho ),( Ki Tae Yoon ),( Si Hyun Bae ),( Eric D. Crown ),( Linda M. Fredr 대한간학회 2021 Gut and Liver Vol.15 No.6

Background/Aims: Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy and safety of G/P in Korean patients with chronic hepatitis C virus (HCV) infection. Methods: The study analyzed pooled data on Korean patients with HCV infection enrolled in the ENDURANCE 1 and 2, SURVEYOR II part 4 and VOYAGE I and II trials, which evaluated the efficacy and safety of 8 or 12 weeks of G/P treatment. The patients were either treatment-naïve or had received sofosbuvir or interferon-based treatment. Efficacy was evaluated by assessing the rate of sustained virologic response at 12 weeks posttreatment (SVR12). Safety was evaluated by monitoring adverse events (AEs) and laboratory assessments. Results: The analysis included 265 patients; 179 (67.5%) were HCV treatment-naïve, and most patients were either subgenotype 1B (48.7%) or 2A (44.5%). In the intention-to-treat population, 262 patients (98.9%) achieved SVR12. Three patients did not achieve SVR12: one had virologic failure and two had non-virologic failures. Most AEs were grade 1/2; eight patients (3.0%) experienced at least one grade ≥3 AE. No serious AEs related to G/P treatment were reported, and grade ≥3 hepatic laboratory abnormalities were rare (0.8%). Conclusions: G/P therapy was highly efficacious and well tolerated in Korean patients with HCV infection, with most patients achieving SVR12. The safety profile was comparable to that observed in a pooled analysis of a global pan-genotypic population of patients with HCV infection who received G/P. (Gut Liver 2021;15:895-903)